Your browser doesn't support javascript.
loading
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.
Pouleau, Blandine; Estoppey, Carole; Suere, Perrine; Nallet, Emilie; Laurendon, Amélie; Monney, Thierry; Pais Ferreira, Daniela; Drake, Adam; Carretero-Iglesia, Laura; Macoin, Julie; Berret, Jérémy; Pihlgren, Maria; Doucey, Marie-Agnès; Gudi, Girish S; Menon, Vinu; Udupa, Venkatesha; Maiti, Abhishek; Borthakur, Gautam; Srivastava, Ankita; Blein, Stanislas; Mbow, M Lamine; Matthes, Thomas; Kaya, Zeynep; Edwards, Claire M; Edwards, James R; Menoret, Emmanuelle; Kervoëlen, Charlotte; Pellat-Deceunynck, Catherine; Moreau, Philippe; Zhukovsky, Eugene; Perro, Mario; Chimen, Myriam.
Afiliação
  • Pouleau B; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Estoppey C; Department of Antibody Engineering, Ichnos Sciences SA, Epalinges, Switzerland.
  • Suere P; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Nallet E; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Laurendon A; Department of Antibody Engineering, Ichnos Sciences SA, Epalinges, Switzerland.
  • Monney T; Department of Antibody Engineering, Ichnos Sciences SA, Epalinges, Switzerland.
  • Pais Ferreira D; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Drake A; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Carretero-Iglesia L; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Macoin J; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Berret J; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Pihlgren M; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Doucey MA; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Gudi GS; Department of Pharmacokinetics and Translational Sciences, Ichnos Sciences Inc, New York, NY.
  • Menon V; Department of Pharmacokinetics and Translational Sciences, Ichnos Sciences Inc, New York, NY.
  • Udupa V; Department of Toxicology, Glenmark Pharmaceuticals Limited, Mumbai, India.
  • Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Srivastava A; Department of Antibody Engineering, Ichnos Sciences SA, Epalinges, Switzerland.
  • Blein S; Department of Antibody Engineering, Ichnos Sciences SA, Epalinges, Switzerland.
  • Mbow ML; Department of Oncology, Ichnos Sciences SA, Epalinges, Switzerland.
  • Matthes T; Hematology Service, Department of Oncology and Clinical Pathology Service, Department of Diagnostics, University Hospital Geneva, Geneva, Switzerland.
  • Kaya Z; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute, University of Oxford, Oxford, United Kingdom.
  • Edwards CM; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute, University of Oxford, Oxford, United Kingdom.
  • Edwards JR; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute, University of Oxford, Oxford, United Kingdom.
  • Menoret E; Nantes Université, INSERM, Centre national de la recherche scientifique, Université d'Angers, Nantes, France.
  • Kervoëlen C; Therassay Core Facility, Department of Onco-Hematology, Capacités, Nantes Université, Nantes, France.
  • Pellat-Deceunynck C; Nantes Université, INSERM, Centre national de la recherche scientifique, Université d'Angers, Nantes, France.
  • Moreau P; Therassay Core Facility, Department of Onco-Hematology, Capacités, Nantes Université, Nantes, France.
  • Zhukovsky E; Nantes Université, INSERM, Centre national de la recherche scientifique, Université d'Angers, Nantes, France.
  • Perro M; SIRIC ILIAD, Angers, Nantes, France.
  • Chimen M; Nantes Université, INSERM, Centre national de la recherche scientifique, Université d'Angers, Nantes, France.
Blood ; 142(3): 260-273, 2023 07 20.
Article em En | MEDLINE | ID: mdl-37192303
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Mieloma Múltiplo Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Mieloma Múltiplo Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article